{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:41:35Z","timestamp":1789764095790,"version":"4.0.1"},"reference-count":7,"publisher":"SAGE Publications","issue":"13-14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1089\/hum.2024.38567.bfs","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T11:36:16Z","timestamp":1721216176000},"page":"413-415","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Pfizer Weighs Next Steps after DMD Therapy Linked to Boy\u2019s Death Fails Phase III Trial"],"prefix":"10.1177","volume":"35","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Pfizer. Pfizer provides update on phase 3 study of investigational gene therapy for ambulatory boys with duchenne muscular dystrophy. June 12 2024. Available from: https:\/\/investors.pfizer.com\/Investors\/News\/news-details\/2024\/Pfizer-Provides-Update-on-Phase-3-Study-of-Investigational-Gene-Therapy-for-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy\/default.aspx"},{"key":"e_1_3_1_3_2","unstructured":"MilliporeSigma. MilliporeSigma signs definitive agreement to acquire mirus bio furthering ambition to be a leading supplier for viral vector manufacturing. May 22 2024. Available from: https:\/\/www.sigmaaldrich.com\/US\/en\/collections\/press\/agreement-to-acquire-mirus-bio [Last accessed: June12 2024]."},{"key":"e_1_3_1_4_2","unstructured":"Intellia Therapeutics. Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002 an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE). June 2 2024. Available from: https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-announces-positive-long-term-data-ongoing [Last accessed: June12 2024]."},{"key":"e_1_3_1_5_2","unstructured":"Evotec. Evotec reports Q1 2024 results and provides corporate update. May 22 2024. Available from: https:\/\/www.evotec.com\/en\/news\/evotec-reports-q1-2024-results-and-provides-corporate-update [Last accessed: June13 2024]."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Philippidis A. Entos expands in-house manufacturing with GMP facility. Genetic Engineering & Biotechnology News. June 5 2024. Available from: https:\/\/www.genengnews.com\/topics\/bioprocessing\/entos-expands-in-house-manufacturing-with-gmp-facility\/ [Last accessed: June12 2024].","DOI":"10.1089\/genedge.6.01.099"},{"key":"e_1_3_1_7_2","unstructured":"Entos Pharmaceuticals. The Challenge: Effective Nucleic Acid Delivery. Available from: https:\/\/www.entospharma.com\/fusogenix [Last accessed: June12 2024]."},{"key":"e_1_3_1_8_2","unstructured":"Ori Biotech. Ori biotech unveils IRO platform at annual international society for cell & gene therapy conference. May 29 2024. Available from: https:\/\/oribiotech.com\/news\/ori-biotech-unveils-iro-platform-at-annual-international-society-for-cell-gene-therapy-conference [Last accessed: June12 2024]."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2024.38567.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.38567.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.38567.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:57:03Z","timestamp":1777449423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2024.38567.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":7,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1089\/hum.2024.38567.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2024.38567.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}